Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products ...
Ratings for Protagonist Therapeutics (NASDAQ:PTGX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view ...
AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel ...
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2026 Earnings Call Transcript January 29, 2026 Takeda Pharmaceutical ...
Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med Vyvanse. Now that the gap between Vyvanse erosion and growth from new ...
As February begins, the U.S. stock market has shown a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting positive sentiment despite recent economic ...
For more details about Takeda’s FY2025 Q3 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as ...
20don MSN
Is Takeda Pharmaceutical Company Limited (TAK) one of the best healthcare stocks to buy for 2026?
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best healthcare stocks to buy for 2026. Takeda Pharmaceutical Company Limited (NYSE:TAK) reported Q3 FY2025 results on January 29, 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results